Sonnet BioTherapeutics Holdings, Inc. (SONN)

Market Cap	2.74M
Revenue (ttm)	92,731
Net Income (ttm)	-8.43M
Shares Out	3.11M
EPS (ttm)	-2.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	67,839
Open	0.931
Previous Close	0.932
Day's Range	0.871 - 0.931
52-Week Range	0.870 - 11.440
Beta	1.05
Analysts	Strong Buy
Price Target	47.85 (+5,337.5%)
Earnings Date	Aug 12, 2024

About SONN

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Dr. Pankaj Mohan Ph.D.
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: SONN

Financial Performance

In 2023, SONN's revenue was $147,805, a decrease of -57.76% compared to the previous year's $349,943. Losses were -$18.83 million, -36.64% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for SONN stock is "Strong Buy." The 12-month stock price forecast is $47.85, which is an increase of 5,337.50% from the latest price.

Price Target

$47.85

(5,337.50% upside)

Analyst Consensus: Strong Buy